Gilead secures FDA nod for Vemlidy to treat chronic HBV infection in children
The current FDA approval expands Vemlidy’s previous indication as a once-daily therapy to treat chronic HBV infection in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Nov 22
The current FDA approval expands Vemlidy’s previous indication as a once-daily therapy to treat chronic HBV infection in…
31 Oct 22
Actemra is indicated for the treatment of hospitalised Covid-19 patients who are on systemic corticosteroids, and require supplemental…
27 Oct 22
Capivasertib plus Faslodex showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to placebo…
26 Oct 22
Tecvayli is an off-the-shelf, subcutaneous therapy, indicated for subcutaneous administration for the treatment of relapsed or refractory multiple…
17 Oct 22
Boehringer Ingelheim is seeking approval in the European Union for its IL-36R inhibitor in generalised pustular psoriasis based…
12 Oct 22
The FDA inspectors discovered that Lilly’s employees had not properly tracked contaminated drugs batches that were supposed to…
11 Oct 22
The drug is indicated for congestion due to fluid overload in adults with New York Heart Association Class…
10 Oct 22
Boostrix was previously approved to prevent tetanus, diphtheria and whooping cough in children aged 10 years and above,…
30 Sep 22
Relyvrio, previously known as AMX0035 in the US, is an oral, fixed-dose combination therapy intended for the treatment…
29 Sep 22
The FDA approval of Dupixent is based on data from two Phase 3 PRIME and PRIME2 clinical trials,…